This study concludes that these antibodies were the main therapeutic agents for a diverse group of pathophysiological disorders such as multiple sclerosis, migraines, etc. This study concluded that eptinezumab, fremanezumab, and galcanezumab CGRP monoclonal antibodies have primitive impacts on the treatment of migraine in humans. Here, CALCA is linked to migraine disorder.